Financial Performance - The group's revenue for the fiscal year 2025 was approximately HKD 644.4 million, an increase of about 9.1% compared to fiscal year 2024[3] - The profit attributable to the company's owners for fiscal year 2025 was approximately HKD 26.3 million, an increase of about HKD 2.1 million or approximately 8.9% from fiscal year 2024[3] - Basic earnings per share for fiscal year 2025 were approximately HKD 0.069, compared to HKD 0.064 for fiscal year 2024[5] - Gross profit for fiscal year 2025 was HKD 295.5 million, compared to HKD 269.9 million in fiscal year 2024[4] - The total comprehensive income for the year was HKD 25.2 million, compared to HKD 19.2 million in the previous year[5] - The group reported a pre-tax profit of HKD 29.9 million for fiscal year 2025, compared to HKD 26.6 million for fiscal year 2024[4] - The group reported a net profit of HKD 26.632 million, compared to HKD 24.189 million in the previous year, indicating an increase of about 10.1%[24] - Adjusted profit before tax for the group was HKD 29.942 million, up from HKD 26.564 million, marking a growth of around 9.0%[24] Dividends and Shareholder Returns - The board proposed a final dividend of HKD 0.03 for fiscal year 2025, up from HKD 0.028 in fiscal year 2024[3] - The group proposed a final dividend of HKD 0.03 per share for 2025, compared to HKD 0.028 per share in 2024, totaling HKD 11.4 million for 2025[43] Assets and Liabilities - Non-current assets increased to HKD 484,322,000 in 2025 from HKD 442,759,000 in 2024, representing a growth of 9.5%[6] - Current assets decreased to HKD 587,649,000 in 2025 from HKD 613,614,000 in 2024, a decline of 4.2%[6] - Total liabilities decreased from HKD 215,820,000 in 2024 to HKD 203,721,000 in 2025, a reduction of 5.6%[6] - Non-current liabilities increased to HKD 86,501,000 in 2025 from HKD 73,887,000 in 2024, an increase of 17.0%[7] - Total equity rose to HKD 781,749,000 in 2025 from HKD 766,666,000 in 2024, reflecting a growth of 2.0%[7] - Cash and cash equivalents decreased to HKD 439,903,000 in 2025 from HKD 489,583,000 in 2024, a decline of 10.1%[6] - The group's total liabilities amounted to HKD 290,222,000 in 2025, slightly up from HKD 289,707,000 in 2024[25] Revenue Segmentation - The external customer revenue for the general medical services segment was HKD 410.825 million, up from HKD 398.388 million, indicating a growth of about 3.6%[24] - The specialty medical services segment reported a loss of HKD 13.114 million, an improvement from a loss of HKD 39.270 million in the previous year[24] - The dental services segment generated revenue of HKD 67.757 million, compared to HKD 58.469 million, reflecting an increase of approximately 15.5%[24] - Revenue from primary healthcare services increased by approximately HKD 12.4 million or 3.1% to about HKD 410.8 million in fiscal year 2025, driven by an increase in patient visits and average spending per visit[45] - Revenue from specialist medical services rose by approximately HKD 31.9 million or 23.8% to about HKD 165.8 million in fiscal year 2025, attributed to an increase in patient visits and average spending per visit[45] - Revenue from dental services increased by approximately HKD 9.3 million or 15.9% to about HKD 67.8 million in fiscal year 2025, mainly due to increased patient visits following the acquisition of Youde Dental[45] Operational Efficiency - The group's administrative and other expenses for fiscal year 2025 were HKD 271.7 million, compared to HKD 264.0 million in fiscal year 2024[4] - The group's service costs increased by approximately HKD 28.0 million or 8.7% to about HKD 349.0 million for the fiscal year 2025, primarily due to increased payments to doctors and dentists[46] - Financing costs decreased to HKD 6.6 million in fiscal year 2025 from HKD 8.2 million in fiscal year 2024[4] - The impairment loss on trade receivables decreased to HKD 10.9 million in 2025 from HKD 11.2 million in 2024[41] Acquisitions and Market Position - The group completed the acquisition of Youde Dental in fiscal year 2025, contributing to overall revenue growth in the dental segment despite competitive pressures[59] - The acquisition of Yau Tak Dental was completed, contributing to a revenue of approximately HKD 67.8 million in FY2025, reflecting a year-on-year growth of about 15.9%[65] - The number of dental service points increased from 15 to 35, a 133% rise compared to FY2024, enhancing patient accessibility and market coverage[66] Community Engagement and Health Initiatives - The group actively participated in community health programs in collaboration with the Hong Kong government, including seasonal flu vaccination and chronic disease management initiatives[71] - The group emphasizes good corporate governance and responsible business practices, aiming to create a positive and lasting impact on the community[89] Digital Transformation and Technology Integration - In the fiscal year 2025, the group achieved significant progress in digital transformation, implementing a comprehensive clinic operation system and an all-channel sales platform to enhance customer satisfaction[70] - The group emphasizes the integration of technology into operations to enhance nursing quality and efficiency, reflecting its commitment to improving healthcare services[70] Employee and Governance - The company employed 402 full-time employees and 207 part-time employees as of June 30, 2025, compared to 388 full-time and 355 part-time employees in the previous year[107] - The company has adopted the corporate governance code as per the listing rules and has complied with all applicable provisions for the fiscal year 2025, except for a deviation regarding the separation of the roles of Chairman and CEO[112]

相关事件 盈健医疗(01419.HK)9月25日举行董事会会议批准年度业绩 盈健医疗(01419.HK)完成收购香港牙科诊所 经营企业75%股权 格隆汇9月15日丨盈健医疗(01419.HK)宣布，公司董事会会议将于2025年9月25日(星期四)在香港九龙九 龙湾常悦道3号企业广场2期12楼举行，藉以(其中包括)批准公司及其附属公司截至2025年6月30日止年 度业绩及其发布，以及考虑派发末期股息之建议(如有)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Human Health Holdings Limited 盈健醫療集團有限公司 ( 於開曼群島註冊成立之有限公司 ) (股份代號：1419) 董事會召開日期 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.43 條作出。 盈健醫療集團有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司董事會會議 將於 2025 年 9 月 25 日（星期四）在香港九龍九龍灣常悅道 3 號企業廣場 2 期 12 樓 舉行，藉以（其中包括）批准本公司及其附屬公司截至 2025 年 6 月 30 日止年度業績 及其發佈，以及考慮派發末期股息之建議（如有）。 承董事會命 盈健醫療集團有限公司 主席 陳健平 香港，2025 年 9 月 15 日 於本公告日期，董事會包括執行董事陳健平先生，銅紫荊星章，太平紳士（亦為行政總 裁）、彭麗嫦醫生及潘振邦先生；獨立非執行董事呂新榮博士、陳裕光先生及陳希文先 生。 ...

致：香港交易及結算所有限公司 公司名稱: 盈健醫療集團有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01419 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD 100,000,000 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上 ...

Group 1 - The core stock price of Yingjian Medical (01419.HK) closed at HKD 1.110 on August 13, down 1.77% from the previous trading day, with an intraday high of HKD 1.160, marking a nearly one-year high [1] - The company experienced a net inflow of HKD 17.59 thousand on that day, with unspecified amounts flowing in and out [1] - Yingjian Medical Group Limited, established in 1997, is one of the largest medical groups in Hong Kong, listed on the Hong Kong Stock Exchange under stock code 1419 [1] Group 2 - The group operates under the brands "Human Health Integrated Medical Centre," "Human Health Medical Centre," and "Perfect Life," providing comprehensive primary healthcare services [1] - Yingjian Medical has over 60 medical centers across Hong Kong, Kowloon, the New Territories, and outlying islands, offering a wide range of services including prevention, health maintenance, diagnosis, and treatment [1] - The company aims to expand its network of medical centers and establish specialized medical service centers, adhering to its corporate culture of "benevolence" to ensure more citizens can access quality healthcare services [1]

Summary of Key Points Core Viewpoint - A total of 142 stocks reached their 52-week highs as of August 12, with notable performers including Yingmei Holdings (02028), Elite Group (01775), and Fuying Global Group (01620) achieving high rates of 164.89%, 84.78%, and 40.63% respectively [1]. Stock Performance - **Top Performers**: - Yingmei Holdings (02028) closed at 0.223 with a peak of 0.249, marking a 164.89% increase [1]. - Elite Group (01775) closed at 0.350 with a peak of 0.425, reflecting an 84.78% increase [1]. - Fuying Global Group (01620) closed at 0.180, reaching its peak at 0.180, showing a 40.63% increase [1]. - **Other Notable Stocks**: - Aoya Group (02425) increased by 34.36% [1]. - Fuyiy International Holdings (01470) saw a rise of 28.30% [1]. - Huajian Medical (01931) experienced a 27.58% increase [1]. 52-Week High Rankings - The ranking of stocks that reached their 52-week highs includes: - Yingmei Holdings (02028) at 164.89% [1]. - Elite Group (01775) at 84.78% [1]. - Fuying Global Group (01620) at 40.63% [1]. 52-Week Low Rankings - The report also highlights stocks that reached their 52-week lows, with notable declines including: - Jiadeng International Group (08153) at -15.25% [4]. - Kun Group (00924) at -12.86% [4]. - Zhongjia Guoxin (00899) at -10.00% [4].

8月12日，截至港股收盘，恒生指数上涨0.25%，报24969.68点。盈健医疗（01419.HK）收报1.13港元/ 股，上涨11.88%，成交量130万股，成交额141.04万港元，振幅14.85%。 最近一个月来，盈健医疗累计涨幅20.24%，今年来累计涨幅29.49%，跑赢恒生指数24.16%的涨幅。 财务数据显示，截至2024年12月31日，盈健医疗实现营业总收入2.92亿元，同比增长6.98%；归母净利 润1557.78万元，同比减少16.03%；毛利率47.09%，资产负债率25.1%。 资料显示，盈健医疗集团有限公司成立于1997年,在香港联合交易所上市(股份代号:1419),是香港最大型 的医疗集团之一。本集团以'盈健综合医务中心(Human Health Integrated Medical Centre)'、'盈健医务中 心(Human Health Medical Centre)'及'优越医疗(PerfectLife)'品牌提供全科医疗服务。集团开设逾60间医 务中心,网络遍布港九新界及离岛。 集团为个人及企业团体提供全面的医疗服务,服务范围涵盖预防、保健、诊症及治疗;门诊更是病人与整 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 盈健醫療集團有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01419 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/ ...

Group 1 - The core viewpoint of the news highlights the performance of Yingjian Medical (盈健医疗) in the Hong Kong stock market, noting a significant increase in its stock price and a comparison of its financial metrics against industry averages [1] - As of July 23, the Hang Seng Index rose by 1.62%, while Yingjian Medical's stock price increased by 13.95%, closing at HKD 0.98 per share with a trading volume of 1.094 million shares [1] - Over the past month, Yingjian Medical has seen a cumulative increase of 6.17%, but it has underperformed compared to the Hang Seng Index, which has risen by 25.27% year-to-date [1] Group 2 - Financial data indicates that Yingjian Medical achieved total revenue of HKD 292 million for the year ending December 31, 2024, reflecting a year-on-year growth of 6.98%, while its net profit attributable to shareholders decreased by 16.03% to HKD 15.5778 million [1] - The company's gross profit margin stands at 47.09%, and its debt-to-asset ratio is 25.1% [1] - In terms of industry valuation, the average price-to-earnings (P/E) ratio for the healthcare equipment and services sector is -1.96x, with a median of 1.36x, while Yingjian Medical's P/E ratio is 15.56x, ranking 25th in the industry [1]

Revenue Performance - The company's revenue for the first half of the fiscal year 2025 was approximately HKD 315.8 million, an increase of about HKD 20.6 million or 7.0% compared to the same period in fiscal year 2024[10]. - Revenue from primary healthcare services increased by approximately HKD 7.7 million or 3.9% to about HKD 206.6 million, driven by an increase in patient visits[11]. - Revenue from specialist medical services rose by approximately HKD 16.1 million or 24.7% to about HKD 81.3 million, attributed to increased patient visits despite a decrease in average spending per visit[11]. - Revenue from dental services decreased by approximately HKD 3.2 million or 10.2% to about HKD 27.9 million, mainly due to a reduction in average spending per visit[11]. - The revenue from the specialist medical division increased to approximately HKD 81.3 million, representing a year-on-year growth of about 24.7%[35]. - The revenue from the general medical division grew by approximately 3.9% compared to the mid-term of fiscal year 2024[33]. - The dental services revenue decreased to approximately HKD 27.9 million from HKD 31.1 million in the mid-term of fiscal year 2024, reflecting market challenges[36]. - Total revenue for the six months ended December 31, 2024, was HKD 315,788,000, an increase of 6.7% compared to HKD 295,190,000 in the same period of 2023[140]. - General medical services revenue reached HKD 206,609,000, up 3.4% from HKD 198,929,000 year-on-year[140]. - Specialist medical services revenue increased by 24.7% to HKD 81,256,000 from HKD 65,152,000[140]. - Dental services revenue decreased by 10.3% to HKD 27,923,000 compared to HKD 31,109,000 in the previous year[140]. Profitability and Margins - The company's net profit for the mid-term of fiscal year 2025 decreased to approximately HKD 16.8 million, a reduction of about HKD 3.2 million or 16.0% compared to the mid-term of fiscal year 2024[27]. - The net profit margin declined from approximately 6.8% in the mid-term of fiscal year 2024 to about 5.3% in the mid-term of fiscal year 2025[27]. - Gross profit increased by approximately HKD 8.2 million or 5.8% to about HKD 148.7 million, with a slight decrease in gross margin from 47.6% to 47.1%[14]. - The gross margin for primary healthcare services decreased from 55.7% to 54.5%, while the gross margin for specialist services increased from 25.7% to 29.7%[19]. - Basic and diluted earnings per share were both HKD 0.044, down from HKD 0.053 in the prior year, reflecting a decline of 16.9%[113]. - Adjusted profit before tax for the six months was HKD 20,066,000, down 16.1% from HKD 23,934,000 in the prior period[142]. - The net profit for the period was HKD 16,822,000, a decrease of 16.5% from HKD 20,033,000 in the previous year[113]. Costs and Expenses - The cost of services provided increased by approximately HKD 12.4 million or 8.0% to about HKD 167.1 million, primarily due to increased doctor fees related to higher revenue from healthcare services[13]. - Administrative and other expenses increased by approximately HKD 6.8 million or 5.6% to about HKD 128.9 million, mainly due to an increase in employee costs[22]. - Total costs of services provided amounted to HKD 167,070,000, an increase from HKD 154,684,000, reflecting a rise in medical supplies and personnel costs[142]. Financial Position - The company reported a net asset value of HKD 771,370,000 as of December 31, 2024, compared to HKD 766,666,000 as of June 30, 2024, reflecting a slight increase of 0.9%[116]. - Total assets as of December 31, 2024, were HKD 1,046,852,000, compared to HKD 1,056,373,000 as of June 30, 2024[114]. - Current assets totaled HKD 610,545,000, slightly down from HKD 613,614,000 at the end of the previous period[114]. - Current liabilities decreased to HKD 193,398,000 from HKD 215,820,000, showing a reduction of 10.4%[114]. - The company’s total non-current liabilities decreased to HKD 65,084,000 as of December 31, 2024, down from HKD 73,887,000 as of June 30, 2024, a reduction of 11.9%[116]. - The company’s cash and cash equivalents increased to HKD 397,626,000 as of December 31, 2024, from HKD 184,207,000 a year earlier, marking a substantial increase of 116.5%[125]. - The company generated a net cash inflow from investing activities of HKD 268,483,000 for the six months ended December 31, 2024, compared to HKD 19,220,000 in the prior year[122]. Strategic Initiatives - The company plans to enhance its position in the dental services market through the acquisition of Youde Dental Clinic, announced on January 3, 2025[36]. - The board maintains a cautiously optimistic outlook for the second half of the fiscal year 2025, recognizing the need to adapt to market changes and seize growth opportunities[57]. - The group has actively explored strategic growth and revenue diversification, aiming to expand market coverage and serve a more diverse customer base[58]. - The company plans to continue focusing on market expansion and new product development as part of its strategic initiatives moving forward[118]. Community and Social Responsibility - The group is committed to ethical behavior and social responsibility, prioritizing environmental sustainability and community engagement[64]. - The group has collaborated with the Hong Kong government to enhance community healthcare services, including seasonal flu vaccination funding and chronic disease management programs[59]. - The expansion of the "Injury Employee Rehabilitation Pilot Program" has led to positive outcomes, benefiting employees injured at work across various industries[37]. - The successful rehabilitation pilot program has increased the return-to-work rate for injured employees, demonstrating the effectiveness of the group's rehabilitation measures[40]. Human Resources - The diverse team of 484 healthcare professionals ensures comprehensive and customer-focused medical and healthcare services[54]. - The group plans to focus on recruiting specialized healthcare professionals to expand its specialized medical services[63]. - As of December 31, 2024, the group had 388 full-time employees and 377 part-time employees, showing a slight increase in full-time staff from 386 the previous year[82]. Investments and Acquisitions - The group has entered into an agreement to acquire 75% of the issued share capital of Youde Dental Clinic Limited for HKD 38,850,000, which will be consolidated into the group's financial statements upon completion[85]. - The limited partnership agreement has been extended to December 31, 2024, and further to June 30, 2025, to enhance business development opportunities in China[78]. - The investment in the limited partnership is recorded at fair value, with a fair value of approximately HKD 58.7 million as of December 31, 2024, representing about 5.7% of the total assets of the group[75]. Governance and Compliance - The group has adopted the corporate governance code as per the listing rules and has complied with all applicable provisions except for the separation of the roles of Chairman and CEO[89]. - The company has adopted the standard code of conduct for securities trading by directors, confirming compliance for the fiscal year 2025[91]. Share Options and Equity - As of December 31, 2024, a total of 3,200,000 options have been granted under the share option plan, with 150,000 options remaining unexercised[94]. - The total number of share options and share rewards that can be granted under the plans is capped at 37,955,223 shares, representing approximately 10% of the issued shares as of the adoption date[99]. - The company has not granted any share options or rewards that require performance targets to be met prior to exercise[100]. - The company has not recognized any stock option expenses for the six months ended December 31, 2024, consistent with the previous period[187].